ArticleDrug design, development and therapy2019

Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways.

Ying Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.